Pharmafile Logo
Pharmafocus logo
Advanced Search

MSD

Showing 15 posts of 247 posts found.

lynparza

Lynparza extends progression-free survival in gBRCAm metastatic pancreatic cancer

February 26, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza, pharma

AstraZeneca and MSD have lifted the curtain on new Phase 3 data for Lynparza (olaparib), confirming that the drug generated …

News
merckwindow_web

Keytruda falls short at Phase 3 in advanced liver cancer

February 20, 2019
Research and Development Cancer, MSD, keytruda, liver cancer, pharma

MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda (pembrolizumab), in combination with best supportive …

News
merckwindow_web

MSD’s Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma

February 18, 2019
Sales and Marketing Cancer, MSD, Merck Sutent, Pfizer, inlyta, keytruda, oncology, rcc, renal cell carcinoma

Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal …

News
merck-keytruda

Keytruda + Inlyta combo beats Pfizer’s chemotherapy Sutent in renal cell carcinoma

February 12, 2019
Manufacturing and Production, Research and Development Cancer, MSD, Pfizer, inlyta, keytruda, pharma, renal cell carcinoma

New data has been revealed on the efficacy of MSD’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib), showing it …

News
merckincweb1

MSD’s Keytruda boosts overall survival by 31% in advanced oesophageal cancer

January 16, 2019
Research and Development Cancer, MSD, keytruda, oesophageal cancer, pharma

MSD has unveiled new Phase 3 data for its blockbuster anti-PD-1 immunotherapy Keytruda (pembrolizumab), showing that the drug succeeded in …

News
merckwindow_web

MSD chalks up two HIV drug approvals in Europe

November 30, 2018
Medical Communications, Sales and Marketing Delstrigo, EU, Europe, HIV, MSD, Pifeltro, pharma

MSD has announced the European approval of two of its products for the treatment of HIV: the single-tablet combination Delstrigo …

News

MSD’s Keytruda to treat melanoma in England on the Cancer Drugs Fund

November 19, 2018
Sales and Marketing England, MSD, NHS, UK, keytruda, melanoma, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) will now be made available to patients in England via the Cancer Drugs Fund, it …

News
merckentranceweb

MSD’s Keytruda improvess overall survival in Phase 3 oesophageal cancer

November 15, 2018
Research and Development Cancer, MSD, PD-L1, keytruda, pharma

MSD has announced new Phase 3 data on its anti-PD-1 therapy Keytruda (pembrolizumab) as a second-line treatment for advanced or …

News
merckincweb2

MSD’s Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer

November 1, 2018
Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or …

News
merckincweb2

First-line Keytruda shows better overall survival in head & neck cancer

October 23, 2018
Manufacturing and Production, Research and Development Cancer, ESMO 2018, MSD, head and neck cancer, keytruda, pharma

MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new …

News
merckincweb

MSD’s Keytruda with Pfizer’s Inlyta beats Sutent in most common kidney cancer

October 19, 2018
Medical Communications, Research and Development Cancer, Kidney cancer, MSD, Pfizer, inlyta, keytruda, pharma

MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, …

News
merckwindow_web

MSD and Samsung Bioepis terminate development of Lantus biosimilar for diabetes

October 15, 2018
Research and Development, Sales and Marketing Lantus, MSD, Samsung Bioepis, Sanofi, biosimilar, diabetes, pharma

MSD has reportedly terminated a previous agreement with Samsung Bioepis which would have seen them collaborate on a biosimilar version …

News
msd

MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar

October 8, 2018
Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis

American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department …

News

Memorial Sloan Kettering Chief resigns from MSD board

October 3, 2018
Research and Development MSD, Memorial Sloan Kettering Cancer Center, pharma

Dr Craig Thompson, Chief Executive of Memorial Sloan Kettering Cancer Center (MSKCC), the renowned non-profit treatment and research institution based …

News
kenneth_c

Kenneth Frazier to continue as CEO as MSD rescinds mandatory retirement policy

September 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kenneth Frazier, MSD, pharma

MSD has pitched a curveball with the news that the company has rescinded its policy mandating that Chief Executive Officers …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026